bluebird bio, Inc. announced that it has completed the first commercial cell collection for LYFGENIA (lovotibeglogene autotemcel), a one-time gene therapy for the treatment of sickle cell disease in patients with a history of vaso-occlusive events. LYFGENIA was approved by the FDA in December 2023 and is the most deeply studied gene therapy for sickle cell disease, with the longest follow-up in the field. The patient?s cells were collected at Children?s National Hospital in Washington, DC, which is part of bluebird?s national network of more than 60 Qualified Treatment Centers (QTCs).

QTCs are selected based on leading expertise in transplant, cell and gene therapy, and sickle cell disease and receive specialized training to administer LYFGENIA.